
|Articles|July 1, 2004
Fighting melanoma
New Orleans - Oblimersen sodium (Genasense), the antisense agent under investigation for advanced malignant melanoma, improved progression-free survival but not overall survival, in a recent phase III trial, Michael J. Millward, M.D. reported here at the annual meeting of the American Society of Clinical Oncology (ASCO).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
4
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
5














